Transgene SA (TNG) - Net Assets
Based on the latest financial reports, Transgene SA (TNG) has net assets worth €-3.60 Million EUR (≈ $-4.21 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.99 Million ≈ $47.92 Million USD) and total liabilities (€44.59 Million ≈ $52.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Transgene SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-3.60 Million |
| % of Total Assets | -8.79% |
| Annual Growth Rate | -1.13% |
| 5-Year Change | -69.74% |
| 10-Year Change | -42.73% |
| Growth Volatility | 117.37 |
Transgene SA - Net Assets Trend (1997–2024)
This chart illustrates how Transgene SA's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Transgene SA for the complete picture of this company's asset base.
Annual Net Assets for Transgene SA (1997–2024)
The table below shows the annual net assets of Transgene SA from 1997 to 2024. For live valuation and market cap data, see Transgene SA (TNG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
-2.61% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
-58.74% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
-43.70% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
+33.75% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
-23.51% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
+79.01% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
+30.66% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
-39.60% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
+75.17% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
-63.05% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
+26.87% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
-43.14% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
-29.59% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
-22.98% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
+167.81% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
-27.23% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
-15.07% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
+484.52% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
+33.35% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
-58.77% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
-37.47% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
-25.02% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
+111.66% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
-37.29% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
-24.51% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
+255.29% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Transgene SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11444942500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €66.15 Million | 435.06% |
| Other Components | €88.79 Million | 583.98% |
| Total Equity | €15.20 Million | 100.00% |
Transgene SA Competitors by Market Cap
The table below lists competitors of Transgene SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Limoneira Co
NASDAQ:LMNR
|
$231.20 Million |
|
LCNB Corporation
NASDAQ:LCNB
|
$231.36 Million |
|
Acadian Timber Corp
TO:ADN
|
$231.37 Million |
|
G1 Secure Solutions Ltd
TA:GOSS
|
$231.43 Million |
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
$231.14 Million |
|
104 Corporation
TW:3130
|
$231.10 Million |
|
Alro Slatina
RO:ALR
|
$231.09 Million |
|
Kisco Holdings
KO:001940
|
$231.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Transgene SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,612,000 to 15,204,000, a change of -408,000 (-2.6%).
- Net loss of 33,971,000 reduced equity.
- Other comprehensive income increased equity by 210,000.
- Other factors increased equity by 33,353,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-33.97 Million | -223.43% |
| Other Comprehensive Income | €210.00K | +1.38% |
| Other Changes | €33.35 Million | +219.37% |
| Total Change | €- | -2.61% |
Book Value vs Market Value Analysis
This analysis compares Transgene SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.13x to 5.72x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | €5.90 | €0.75 | x |
| 1998-12-31 | €12.51 | €0.75 | x |
| 1999-12-31 | €9.42 | €0.75 | x |
| 2000-12-31 | €5.82 | €0.75 | x |
| 2001-12-31 | €8.46 | €0.75 | x |
| 2002-12-31 | €5.30 | €0.75 | x |
| 2003-12-31 | €3.31 | €0.75 | x |
| 2004-12-31 | €1.37 | €0.75 | x |
| 2006-12-31 | €1.17 | €0.75 | x |
| 2007-12-31 | €5.43 | €0.75 | x |
| 2008-12-31 | €4.11 | €0.75 | x |
| 2009-12-31 | €3.02 | €0.75 | x |
| 2010-12-31 | €6.46 | €0.75 | x |
| 2011-12-31 | €4.35 | €0.75 | x |
| 2012-12-31 | €3.06 | €0.75 | x |
| 2013-12-31 | €1.73 | €0.75 | x |
| 2014-12-31 | €1.82 | €0.75 | x |
| 2015-12-31 | €0.67 | €0.75 | x |
| 2016-12-31 | €0.80 | €0.75 | x |
| 2017-12-31 | €0.44 | €0.75 | x |
| 2018-12-31 | €0.59 | €0.75 | x |
| 2019-12-31 | €0.80 | €0.75 | x |
| 2020-12-31 | €0.60 | €0.75 | x |
| 2021-12-31 | €0.74 | €0.75 | x |
| 2022-12-31 | €0.38 | €0.75 | x |
| 2023-12-31 | €0.16 | €0.75 | x |
| 2024-12-31 | €0.13 | €0.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Transgene SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -223.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -534.72%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 2.77x
- Recent ROE (-223.43%) is below the historical average (-65.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -57.33% | -176.71% | 0.22x | 1.46x | €-13.93 Million |
| 1998 | -47.62% | -300.00% | 0.14x | 1.15x | €-42.35 Million |
| 1999 | -32.85% | -421.36% | 0.06x | 1.21x | €-23.77 Million |
| 2000 | -64.62% | -475.85% | 0.10x | 1.38x | €-25.96 Million |
| 2001 | -29.81% | -1741.83% | 0.01x | 1.17x | €-29.31 Million |
| 2002 | -33.34% | -834.36% | 0.03x | 1.21x | €-23.93 Million |
| 2003 | -60.47% | -834.67% | 0.05x | 1.33x | €-24.33 Million |
| 2004 | -143.93% | -814.84% | 0.10x | 1.79x | €-21.91 Million |
| 2006 | -116.08% | -397.24% | 0.17x | 1.72x | €-23.93 Million |
| 2007 | -4.98% | -19.70% | 0.22x | 1.16x | €-16.61 Million |
| 2008 | -19.10% | -129.04% | 0.11x | 1.34x | €-27.42 Million |
| 2009 | -39.89% | -232.44% | 0.12x | 1.44x | €-34.20 Million |
| 2010 | -18.64% | -242.48% | 0.06x | 1.22x | €-52.58 Million |
| 2011 | -30.85% | -301.99% | 0.07x | 1.37x | €-57.77 Million |
| 2012 | -43.39% | -1099.87% | 0.02x | 1.61x | €-53.16 Million |
| 2013 | -75.69% | -1113.48% | 0.03x | 2.22x | €-48.52 Million |
| 2014 | -67.59% | -1950.04% | 0.02x | 1.96x | €-55.74 Million |
| 2015 | -174.69% | -3165.46% | 0.01x | 3.80x | €-49.03 Million |
| 2016 | -54.21% | -1074.47% | 0.02x | 2.64x | €-29.86 Million |
| 2017 | -114.90% | -1537.59% | 0.02x | 3.59x | €-35.08 Million |
| 2018 | 21.87% | 601.20% | 0.01x | 2.96x | €4.36 Million |
| 2019 | -28.62% | -141.43% | 0.12x | 1.76x | €-25.37 Million |
| 2020 | -36.72% | -618.92% | 0.03x | 1.70x | €-23.48 Million |
| 2021 | -29.76% | -200.18% | 0.10x | 1.52x | €-26.72 Million |
| 2022 | -86.70% | -1049.58% | 0.05x | 1.76x | €-36.59 Million |
| 2023 | -143.02% | -282.63% | 0.17x | 2.90x | €-23.89 Million |
| 2024 | -223.43% | -534.72% | 0.15x | 2.77x | €-35.49 Million |
Industry Comparison
This section compares Transgene SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $54,195,048
- Average return on equity (ROE) among peers: -104.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Transgene SA (TNG) | €-3.60 Million | -57.33% | N/A | $231.18 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $123.48 Million |
| Abivax SA (ABVX) | $11.78 Million | -260.03% | 3.39x | $6.97 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $111.73 Million |
| Aelis Farma SA (AELIS) | $1.20 Million | -263.37% | 5.00x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $6.83 Million | -373.49% | 2.98x | $1.03 Million |
| Cellectis (ALCLS) | $450.27 Million | -17.48% | 0.11x | $282.27 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $21.67 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $30.11 Million |
| Integragen (ALINT) | $2.19 Million | 0.70% | 3.39x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more